Calidi Biotherapeutics Past Earnings Performance
Past criteria checks 0/6
Calidi Biotherapeutics's earnings have been declining at an average annual rate of -33.8%, while the Biotechs industry saw earnings growing at 19.1% annually.
Key information
-33.8%
Earnings growth rate
-21.9%
EPS growth rate
| Biotechs Industry Growth | 17.0% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 31 Mar 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Calidi Biotherapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Mar 24 | 0 | -30 | 17 | 13 |
| 31 Dec 23 | 0 | -29 | 16 | 13 |
| 30 Sep 23 | 0 | -29 | 17 | 11 |
| 30 Jun 23 | 0 | -32 | 16 | 10 |
| 31 Mar 23 | 0 | -24 | 15 | 8 |
| 31 Dec 22 | 0 | -25 | 16 | 7 |
| 30 Sep 22 | 0 | -21 | 11 | 6 |
| 31 Dec 21 | 0 | -11 | 6 | 4 |
Quality Earnings: CLDI is currently unprofitable.
Growing Profit Margin: CLDI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLDI is unprofitable, and losses have increased over the past 5 years at a rate of 33.8% per year.
Accelerating Growth: Unable to compare CLDI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLDI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (0.5%).
Return on Equity
High ROE: CLDI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.